Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean Nolan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 99
- Beta
- 1.17
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 8.37
Financials
Revenue
$0.00-100.0%Net Income
$-46.64MEBITDA
$-46.23MFree Cash Flow
$-40.42MEPS (diluted)
$-0.13Shares Outstanding (diluted)
369.04M+2332.7%Operating Expenses
$50.78MCash & Debt
$455.41MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.77M | $-109.00M | $-0.34 |
| 2024 | $8.33M | $-89.30M | $-0.36 |
| 2023 | $15.45M | $-111.57M | $-0.96 |
| 2022 | $2.50M | $-166.01M | $-3.78 |
| 2021 | $0.00 | $-174.52M | $-4.64 |
| 2020 | $0.00 | $-43.00M | $-3.40 |
| 2019 | $0.00 | $-1.11M | $-0.03 |
Valuation
TSHAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-80.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·5d ago·Negative
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations sup…
View source ↗ - Newsseekingalpha.com·24d ago·Positive
…oes Not Require The Fastest Approval Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivotal data collection and manufacturing scale-up without immediate dependence on accelerated regulatory filing. TSHA-102's early data show deepening, durable functional gains in Rett patients, but pivotal efficacy, safety, and manufacturing qual…
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Negative
Taysha Gene Therapies Q2 Earnings Call Highlights Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.14 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.13 vs $-0.11miss
- Wed, May 6$-0.12 vs $-0.10miss
- Thu, Mar 19$-0.08 vs $-0.11beat
- Tue, Nov 4$-0.09 vs $-0.09beat
- Tue, Aug 12$-0.09 vs $-0.07miss
- Thu, May 15$-0.08 vs $-0.08beat
Estimates and results for TSHA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TSHA officers and directors.
- Bought
- $21.2m
- Sold
- $8.0m
8 trades
21 trades
- Nagendran Sukumarsold
- Nagendran Sukumarsold
- Alam Kamransold
- Nagendran Sukumarsold
- Nolan Sean P.sold
- Alam Kamransold
- Nagendran Sukumarsold
- Nolan Sean P.sold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TSHA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.